HLB said on the 26th that U.S. subsidiary Elevar Therapeutics (hereafter Elevar) and partner Jiangsu Hengrui Pharmaceuticals on the 23rd (local time) completed resubmitting a new drug application to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results